Sacituzumab govitecan 是一种抗体偶联药物,由靶向人类滋养层细胞表面抗原 2 (Trop-2) 的抗体组成,该抗体在大多数乳腺癌中表达,通过专有的可水解连接物与SN-38(拓扑异构酶I抑制剂)偶联。 研究方法 这是一项随机3期临床试验。研究者...
Trial was enrolled at Clinical Trials.gov as Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0: https://clinicaltrials.gov/study/NCT03995706?cond=NCT03995706. Study preregistered 6/17/19. Primary study activities conducted from 7/17/19 to 6/3/22. The preregistered trial ...
Fig. 8.Efficacy of sacituzumab govitecan (top) and immune checkpoint inhibitors (bottom) in clinical trials. National Clinical Trial (NCT) number is indicated for registered trials, with trial name in parentheses. (E) Experimental and (C) Control treatments are listed on the same line as...
简要标题 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer 临床分期 Phase 3 招募状态 Active, not recruiting 首次公开日期 2020-10-20 条件/疾病 Triple Negative Breast Cancer | HER2-negative Breast Cancer 干预/治疗 Sacituzumab govitecan | Capecitabine | Carboplatin | Cisplatin 申办方 Germa...
In a clinical trial, sacituzumab govitecan therapy significantly improved the duration adults with metastatic HR+/HER2? breast cancer survived without their disease progressing, along with overall survival time, versus standard chemotherapy. The tolerability profile of sacituzumab govitecan was generally...
Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and chec
Sacituzumabgovitecan(IMMU-132),anantitrophoblasticcell-surfaceantigen(anti-Trop-2)humanizedantibody-SN-38conjugate,hadencouragingefficacyinthephase1clinicaltrial.ThisreportfurtherexaminesthepharmacokineticsandsafetyofmultiplecyclesofIMMU-132atdosesof8or10mg/kginpatientswithdiverseadvancedepithelialcancers.METHODS:...
Sacituzumab govitecan-hziy produced comparable efficacy outcomes for patients with metastatic triple-negative breast cancer who had a higher incidence of grade 2 or 3 diarrhea and neutropenia vs patients in the overall population, according to a post hoc analysis of the...
TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at...
Conference|ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases....